(Q34581815)

3 August 2017

title

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias (English)

1 reference

3 August 2017

0 references

1 reference

Bataille R

1

1 reference

3 August 2017

Jourdan M

series ordinal

2

1 reference

3 August 2017

Zhang XG

series ordinal

3

1 reference

3 August 2017

Klein B

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 December 1989

1 reference

Journal of Clinical Investigation

3 August 2017

published in

1 reference

3 August 2017

volume

84

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

2008-2011

1 reference

Staging and kinetics of multiple myeloma.

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=304085

Production of hybridoma growth factor by human monocytes.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=304085

Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=304085

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=304085

Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=304085

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=304085

Multiple actions of interleukin 6 within a cytokine network

7 July 2018

1 reference

12 December 2020

Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma

1 reference

12 December 2020

Clinical evaluation of response or escape to chemotherapy and of survival of patients with multiple myeloma. A prospective study of 202 patients (1975-1982)

1 reference

12 December 2020

A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation

1 reference

12 December 2020

Apparent interleukin 2 (IL-2) inhibitory activity of human serum is due to rapid killing of IL-2-dependent mouse cells

1 reference

12 December 2020

Interleukin 6 (IL-6) in serum and urine of renal transplant recipients

1 reference

12 December 2020

Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system

1 reference

12 December 2020

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

12 December 2020

Functional discrimination between interleukin 6 and interleukin 1

1 reference

12 December 2020

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1172/JCI114392

1 reference

3 August 2017

1 reference

3 August 2017

1 reference